Healthcare entity
market-trends is the sole category represented across all 1 tracked stories. Dr. Chae-Yong Kim is most often covered alongside Asian Society for Neuro-Oncology (ASNO) 2026 Annual Meeting, which appears in 1 of these 1 story. Their average consequence score of 6 sits level with the 6 recorded across the beat in that window.
Last mentioned: Jul 27, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
market-trends is the sole category represented across all 1 tracked stories. Dr. Chae-Yong Kim is most often covered alongside Asian Society for Neuro-Oncology (ASNO) 2026 Annual Meeting, which appears in 1 of these 1 story. Their average consequence score of 6 sits level with the 6 recorded across the beat in that window. Each story carries 2 original sources on average, compared with 2.2 for the broader beat in this window. We currently track 1 Healthcare story that mention Dr. Chae-Yong Kim, all published on July 27, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 23 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Dr. Chae-Yong Kim. Shared-story counts are live from our verified record — not editorial picks.
Press Release Issued
Rznomics announces the presentation and key findings via PRNewswire, making the data public to investors and the biomedical community.
Interim Data Presentation at ASNO 2026
Dr. Chae-Yong Kim of Seoul National University Bundang Hospital delivers oral presentation on interim Phase 1/2a results of RZ-001 in recurrent glioblastoma, reporting safety and early efficacy signals.
Rznomics' RNA-based gene therapy RZ-001 demonstrates encouraging interim safety and efficacy in recurrent glioblastoma, with no dose-limiting toxicities and prolonged disease control in a Phase 1/2a trial presented at ASNO 2026.
Source: prnewswire.com · manilatimes.net
Dr. Chae-Yong Kim is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
